Last reviewed · How we verify

NCT05606120

H-35 CL TRAUMA Cemented Femoral Stem

Completed Last updated 15 January 2026
What this trial tests

trial testing CL TRAUMA femoral stem in Arthroplasty in 54 participants. Completed in 17 September 2025.

Timeline
1 December 2022
Primary endpoint
23 January 2025
17 September 2025

Quick facts

Lead sponsorLimacorporate S.p.a
StatusCompleted
Study typeOBSERVATIONAL
Enrollment54
Start date1 December 2022
Primary completion23 January 2025
Estimated completion17 September 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Limacorporate S.p.a

Who can join

18 and older, any sex, with Arthroplasty or Replacement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study design: monocentric, retrospective, observational and post-market clinical study. Purpose: To demonstrate the safety and performance of CL TRAUMA femoral stem. The eligible study population is represented by the entire population that underwent a hip replacement with CL TRAUMA femoral stem from 2017 to 2023 at Azienda Ospedaliera di Padova (IT) in accordance with the indication for use of the product.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Arthroplasty

Currently open trials in the same condition.

Other Limacorporate S.p.a trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05606120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing